Table 3. Subgroup analyses for CD44 rs13347 and cancers under different genetic models.
| Genetic models | N | OR [95% CI] | P (OR) | Model (method) | I-square (%) | P (H) | P (Begg) | P (Egger) |
|---|---|---|---|---|---|---|---|---|
| Allele contrast | ||||||||
| Overall | 10 | 1.391 [1.172–1.650] | <0.001 | R (D-L) | 86.6 | <0.001 | 0.210 | 0.117 |
| Chinese | 8 | 1.466 [1.218–1.765] | <0.001 | R (D-L) | 87.8 | <0.001 | — | — |
| Indian | 2 | 1.100 [0.891–1.357] | 0.376 | R (D-L) | 0.0 | 0.523 | — | — |
| PB | 5 | 1.607 [1.367–1.890] | <0.001 | R (D-L) | 78.7 | 0.001 | — | — |
| HB | 5 | 1.181 [0.869–1.605] | 0.288 | R (D-L) | 86.3 | <0.001 | — | — |
| NPC | 2 | 2.085 [1.841–2.361] | <0.001 | R (D-L) | 0.0 | 0.934 | — | — |
| BC | 2 | 1.287 [0.844–1.965] | 0.242 | R (D-L) | 80.5 | 0.024 | — | — |
| Dominant model | ||||||||
| Overall | 10 | 1.462 [1.176–1.818] | 0.001 | R (D-L) | 86.9 | <0.001 | 0.210 | 0.081 |
| Chinese | 8 | 1.571 [1.242–1.988] | <0.001 | R (D-L) | 87.7 | <0.001 | — | — |
| Indian | 2 | 1.076 [0.844–1.373] | 0.554 | R (D-L) | 0.0 | 0.610 | — | — |
| PB | 5 | 1.782 [1.451–2.189] | <0.001 | R (D-L) | 78.7 | 0.001 | — | — |
| HB | 5 | 1.182 [0.835–1.673] | 0.347 | R (D-L) | 83.7 | <0.001 | — | — |
| NPC | 2 | 2.392 [2.040–2.806] | <0.001 | R (D-L) | 0.0 | 0.802 | — | — |
| BC | 2 | 1.348 [0.786–2.311] | 0.277 | R (D-L) | 84.0 | 0.012 | — | — |
| Recessive model | ||||||||
| Overall | 10 | 1.810 [1.440–2.275] | <0.001 | R (D-L) | 52.1 | 0.027 | 0.371 | 0.563 |
| Chinese | 8 | 1.858 [1.443–2.393] | <0.001 | R (D-L) | 60.8 | 0.013 | — | — |
| Indian | 2 | 1.417 [0.745–2.697] | 0.288 | R (D-L) | 0.0 | 0.570 | — | — |
| PB | 5 | 1.945 [1.545–2.447] | <0.001 | R (D-L) | 38.4 | 0.165 | — | — |
| HB | 5 | 1.562 [0.948–2.573] | 0.080 | R (D-L) | 63.7 | 0.026 | — | — |
| NPC | 2 | 2.954 [2.181–4.001] | <0.001 | R (D-L) | 0.0 | 0.787 | — | — |
| BC | 2 | 1.746 [1.300–2.346] | <0.001 | R (D-L) | 0.0 | 0.388 | — | — |
| Homozygous model | ||||||||
| Overall | 10 | 2.122 [1.576–2.857] | <0.001 | R (D-L) | 69.9 | <0.001 | 0.210 | 0.374 |
| Chinese | 8 | 2.248 [1.624–3.110] | <0.001 | R (D-L) | 74.6 | <0.001 | — | — |
| Indian | 2 | 1.437 [0.752–2.748] | 0.273 | R (D-L) | 0.0 | 0.543 | — | — |
| PB | 5 | 2.489 [1.876–3.301] | <0.001 | R (D-L) | 55.7 | 0.061 | — | — |
| HB | 5 | 1.642 [0.877–3.074] | 0.121 | R (D-L) | 75.9 | 0.002 | — | — |
| NPC | 2 | 4.106 [3.002–5.617] | <0.001 | R (D-L) | 0.0 | 0.827 | — | — |
| BC | 2 | 1.917 [1.050–3.501] | 0.034 | R (D-L) | 35.6 | 0.213 | — | — |
| Heterozygous model | ||||||||
| Overall | 10 | 1.389 [1.133–1.702] | 0.002 | R (D-L) | 83.5 | <0.001 | 0.283 | 0.053 |
| Chinese | 8 | 1.482 [1.190–1.846] | <0.001 | R (D-L) | 84.3 | <0.001 | — | — |
| Indian | 2 | 1.040 [0.808–1.339] | 0.758 | R (D-L) | 0.0 | 0.727 | — | — |
| PB | 5 | 1.686 [1.390–2.044] | <0.001 | R (D-L) | 73.4 | 0.005 | — | — |
| HB | 5 | 1.124 [0.833–1.518] | 0.445 | R (D-L) | 76.1 | 0.002 | — | — |
| NPC | 2 | 2.152 [1.821–2.544] | <0.001 | R (D-L) | 0.0 | 0.613 | — | — |
| BC | 2 | 1.312 [0.801–2.150] | 0.281 | R (D-L) | 79.5 | 0.027 | — | — |
OR: odds ratio. CI: confidence intervals. N: number of included studies. R: random-effects model. D-L: DerSimonian-Laird method. P (H): P for heterogeneity. PB: population-based. HB: hospital-based. NPC: nasopharyngeal carcinoma. BC: breast cancer. P-values < 0.05 were considered as statistically significant and are highlighted in bold font in the table.